Meg Jardine's Publications

An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials
Journal articles
2021
International Journal of Cardiology
Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes
Journal articles
2021
Diabetes, Obesity and Metabolism
Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria a credence secondary analysis
Journal articles
2021
Clinical Journal of the American Society of Nephrology
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program
Journal articles
2021
American Journal of Kidney Diseases
Acute interstitial nephritis and nephrogenic diabetes insipidus following treatment with sulfamethoxazole-trimethoprim and temozolomide
Journal articles
2021
Nephrology
Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis
Journal articles
2021
Diabetes, Obesity and Metabolism
Sodium-glucose cotransporter 2 inhibition: Which patient with chronic kidney disease should be treated in the future?
Journal articles
2021
Nephrology Dialysis Transplantation
Corrigendum
Journal articles
2021
ESC Heart Failure
Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial
Preprints
2021
Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus
Conference Abstracts
2021
Metabolism
Effects of canagliflozin in patients with baseline eGFR <30 mlmin per 1.73 msup2sup: Subgroup analysis of the randomized CREDENCE trial
Journal articles
2020
Clinical Journal of the American Society of Nephrology
How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?
Journal articles
2020
Kidney and Blood Pressure Research
Prevalence, incidence and risk factors of diabetes in Australian adults aged 45 years: A cohort study using linked routinely-collected data
Journal articles
2020
Journal of Clinical and Translational Endocrinology
Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: A post hoc analysis from the Credence trial
Journal articles
2020
Journal of the American Society of Nephrology
DRUG INDUCED ACUTE INTERSTITIAL NEPHRITIS ASSOCIATED WITH NEPHROGENIC DIABETES INSIPIDUS
Conference Papers
2020
NEPHROLOGY
GLOMERULAR DISEASE REGISTRY AND BIOBANK (GRIT)
Conference Abstracts
2020
NEPHROLOGY
VARIABILITY IN EGFR AND THE RISK OF MAJOR CLINICAL OUTCOMES IN DIABETES: RESULTS FROM ADVANCE
Conference Abstracts
2020
NEPHROLOGY
THE FILTRATION IN THE NEUROPATHY OF END-STAGE KIDNEY DISEASE (FINESSE) RANDOMISED CONTROLLED TRIAL
Conference Abstracts
2020
NEPHROLOGY
A randomized trial on the effect of phosphate reduction on vascular end points in CKD (improve-CKD)
Journal articles
2020
Journal of the American Society of Nephrology
Response to: Loutradis et al. Longer Dialysis Sessions Improve Cardiac Systolic Function by Reducing Myocardial Stunning
Journal articles
2020
Journal of Cardiac Failure
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial
Journal articles
2020
The Lancet Diabetes and Endocrinology
Therapy escalation following an elevated hbainf1cinf in adults aged 45 years and older living with diabetes in Australia: A real-world observational analysis
Journal articles
2020
Diabetes Care
The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program
Journal articles
2020
International Journal of Cardiology
Identifying critically important cardiovascular outcomes for trials in hemodialysis: An international survey with patients, caregivers and health professionals
Journal articles
2020
Nephrology Dialysis Transplantation
Forgotten Technology in the COVID-19 Pandemic: Filtration Properties of Cloth and Cloth MasksA Narrative Review
Journal articles
2020
Mayo Clinic Proceedings
International consensus definitions of clinical trial outcomes for kidney failure: 2020
Journal articles
2020
Kidney International

Previous Next

Meg Jardine's Publications

An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials

Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes

Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria a credence secondary analysis

Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program

Acute interstitial nephritis and nephrogenic diabetes insipidus following treatment with sulfamethoxazole-trimethoprim and temozolomide

Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis

Sodium-glucose cotransporter 2 inhibition: Which patient with chronic kidney disease should be treated in the future?

Corrigendum

Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial

Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus

Effects of canagliflozin in patients with baseline eGFR <30 mlmin per 1.73 msup2sup: Subgroup analysis of the randomized CREDENCE trial

How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?

Prevalence, incidence and risk factors of diabetes in Australian adults aged 45 years: A cohort study using linked routinely-collected data

Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: A post hoc analysis from the Credence trial

DRUG INDUCED ACUTE INTERSTITIAL NEPHRITIS ASSOCIATED WITH NEPHROGENIC DIABETES INSIPIDUS

GLOMERULAR DISEASE REGISTRY AND BIOBANK (GRIT)

VARIABILITY IN EGFR AND THE RISK OF MAJOR CLINICAL OUTCOMES IN DIABETES: RESULTS FROM ADVANCE

THE FILTRATION IN THE NEUROPATHY OF END-STAGE KIDNEY DISEASE (FINESSE) RANDOMISED CONTROLLED TRIAL

A randomized trial on the effect of phosphate reduction on vascular end points in CKD (improve-CKD)

Response to: Loutradis et al. Longer Dialysis Sessions Improve Cardiac Systolic Function by Reducing Myocardial Stunning

Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial

Therapy escalation following an elevated hbainf1cinf in adults aged 45 years and older living with diabetes in Australia: A real-world observational analysis

The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program

Identifying critically important cardiovascular outcomes for trials in hemodialysis: An international survey with patients, caregivers and health professionals

Forgotten Technology in the COVID-19 Pandemic: Filtration Properties of Cloth and Cloth MasksA Narrative Review

International consensus definitions of clinical trial outcomes for kidney failure: 2020

The George Institute for Global Health

The George Institute country sites:

Acknowledgement of Country